Deals Shaping The Medical Industry, April 2014
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced February through March 2014.
You may also be interested in...
Worryingly, however, British consumers are also increasingly turning to social media for health information, and rejecting it if it conflicts with what they believe, or if it is not based on personal experience.
CEO Nello Mainolfi talked to Scrip about Kymera’s pipeline expansion, which will prioritize oral targeted protein degraders in immunology, including two new assets moving into the clinic.
Despite Mark’s relatively upbeat attitude, FDA experts warn that even absent a government shutdowns or minimally impactful ones, the current cycle of continuing resolutions and the lingering threat of budget sequestration is harmful to the agency’s operation.